Global Atopic Dermatitis Treatment Market, By Administration (Injectable, Topical, Oral), Drug Type (Antibiotics, Antihistamines, Corticosteroids, Emollients, Calcineurin Inhibitors, Immunomodulators, Off-Label Therapies, Systemic Agents, PDE4 Inhibitor, Interleukin Inhibitor), End Users (Hospital, Clinic, Home Care), Distribution Channel (Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores, Pharmacies, Dermatology Clinics) - Industry Trends and Forecast to 2030.
Atopic Dermatitis Treatment Market Analysis and Size
Atopic dermatitis or atopic eczema treatment refers to a holistic approach to treat atopic dermatitis. The treatment for chronic skin diseases includes rehydrating the skin using emollients and topical steroids in order to reduce inflammation and itching of skin. The disease is categorized as modifiable, which includes inhalant and food allergens and non-modifiable and factors include genetics or heritability.
The increase in the incidences of atopic dermatitis (AD) among populations across the globe acts as one of the major factors driving the growth of atopic dermatitis treatment market. The growth in awareness regarding the availability of treatments for the disease among people and the increase in initiatives undertaken by governments to provide better and more affordable treatment accelerate the atopic dermatitis treatment market growth. The presence of favorable reimbursement policies and the rise in the popularity of these treatments with the help of digital advertisements further influence the atopic dermatitis treatment market. Additionally, growth in the aging population, improving healthcare infrastructure, and a surge in healthcare expenditure positively affect the atopic dermatitis treatment market.
Data Bridge Market Research analyses that the Atopic Dermatitis Treatment Market was valued at USD 1,426.44 million in 2022 and is further estimated to reach USD 3,026.71 million by 2030 and is expected to grow at a CAGR of 9.86% during the forecast period of 2023 to 2030. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Atopic Dermatitis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 – 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Administration (Injectable, Topical, Oral), Drug Type (Antibiotics, Antihistamines, Corticosteroids, Emollients, Calcineurin Inhibitors, Immunomodulators, Off-Label Therapies, Systemic Agents, PDE4 Inhibitor, Interleukin Inhibitor), End Users (Hospital, Clinic, Home Care), Distribution Channel (Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores, Pharmacies, Dermatology Clinics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (U.S.), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switzerland), LEO Pharma A/S (Denmark), Regeneron Pharmaceuticals Inc. (U.S.), Astellas Pharma Inc. (Japan), Pfizer Inc. (U.S.), GALDERMA LABORATORIES, L.P. (U.S.), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Encore Dermatology, Inc. (U.S.), GSK plc (U.K.), AstraZeneca (U.K.), Bausch Health Companies Inc. (Canada) among other
|
|
Market Opportunities
|
|
Market Definition
The atopic dermatitis treatment market refers to the market of products and treatments used in the treatment and management of atopic dermatitis, for instance, eczema Atopic dermatitis is a chronic inflammatory skin disease characterized by dry, itchy, and inflamed skin. It is a common disease that affects people of all ages, but it mostly starts in early childhood.
The atopic dermatitis treatment market includes a variety of medications, topical creams and ointments, immunosuppressants, moisturizers, and other treatments designed to relieve symptoms, reduce inflammation, and control the condition. These treatments can be prescription or over-the-counter.
Atopic Dermatitis Treatment Market Dynamics
Drivers
- Increasing Prevalence of Atopic Dermatitis
The increasing prevalence of atopic dermatitis is a major market driver. This disease affects a large part of the world's population, increasing the demand for effective treatment options.
- Growing Advancements in Treatment Technologies
The growth of the atopic dermatitis treatment market is offset by continued advances in therapeutic technologies such as the development of targeted biologics and topical formulations. These innovations provide improved efficacy and safety profiles, improving patient outcomes.
Opportunity
- Emerging Atopic Dermatitis Treatment Market
Expanding healthcare infrastructure in emerging markets provides a significant opportunity for the atopic dermatitis treatment market. As economic growth and healthcare costs increase in these regions, the demand for effective treatment options is expected to increase, creating a favorable market environment.
Restraints
- High Cost Associated with Treatment
The high cost associated with the treatment of atopic dermatitis significantly limits the market. The costs of long-term care, including medications and wellness visits, can be burdensome for patients and limit their access to appropriate treatment options.
Challenges
- Lack of Adherence to Treatment
Adherence to treatment regimens is a challenge in the management of atopic dermatitis, and patients may have difficulty maintaining long-term adherence to topical and systemic medications, which may impact treatment outcomes. There is addressing this challenge requires comprehensive patient education and support.
This Atopic Dermatitis Treatment Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the atopic dermatitis treatment market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In June 2022, Sanofi announced the US Food and Drug Administration's approval of Dupixent (dupilumab) for children aged 6 months to 5 years with atopic dermatitis.
- In January 2022, AbbVie Inc. announced that the US FDA has approved RINVOQ (upadacitinib) for the treatment of severe atopic dermatitis in children and adults 12 years of age and older. RINVOQ is recommended for patients who have not responded to previous injection or tablet treatments.
Global Atopic Dermatitis Treatment Market Scope
The atopic dermatitis treatment market is segmented on the basis of type, application, portability, mode of operation, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Administration
- Injectable
- Topical
- Oral
Drug Type
- Antibiotics
- Antihistamines
- Corticosteroids
- Emollients
- Calcineurin inhibitors
- Immunomodulators
- Off-label therapies
- Systemic agents
- PDE4 inhibitor
- Interleukin inhibitors.
End Users
- Hospital
- Clinic
- Homecare
Distribution Channel
- Pharmacies
- Hospital pharmacies
- Online pharmacies
- Drug stores
- Pharmacies and dermatology clinic
Global Atopic Dermatitis Treatment Market Regional Analysis/Insights
The atopic dermatitis treatment market is analyzed, and market size insights and trends are provided by, administration, drug type, end users, and distribution channel, as referenced above.
The countries covered in the global atopic dermatitis treatment market report are the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the atopic dermatitis treatment market due to the new product launches and early treatment adoption within the region. Asia-Pacific is expected to witness the fastest growth during the forecast period because of the rise in healthcare expenditure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The atopic dermatitis treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the atopic dermatitis treatment market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the atopic dermatitis treatment market. The data is available for the historic period 2012-2022.
Competitive Landscape and Atopic Dermatitis Treatment Market Share Analysis
The atopic dermatitis treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the atopic dermatitis treatment market are:
- Boehringer Ingelheim International GmbH (Germany)
- AbbVie Inc. (U.S.)
- Bayer AG (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Novartis AG (Switzerland)
- LEO Pharma A/S (Denmark)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- Pfizer Inc. (U.S.)
- GALDERMA LABORATORIES, L.P. (U.S.)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Encore Dermatology, Inc. (U.S.)
- GSK plc (U.K.)
- AstraZeneca (U.K.)
- Bausch Health Companies Inc. (Canada)
SKU-